{
    "body": "What gene test is recommended for clopidogrel?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18004210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18577829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19706858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22088980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20435227", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22464343", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20083681", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17681590", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22154242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21803320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22974536"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0070166", 
            "o": "http://linkedlifedata.com/resource/umls/label/A0173515"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0173515", 
            "o": "clopidogrel"
        }, 
        {
            "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
            "s": "http://linkedlifedata.com/resource/umls/label/A12101557", 
            "o": "http://www.w3.org/2008/05/skos-xl#Label"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A12785306", 
            "o": "Clopidogrel"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0173516", 
            "o": "MeSH"
        }, 
        {
            "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10928568", 
            "o": "http://www.w3.org/2008/05/skos-xl#Label"
        }
    ], 
    "ideal_answer": [
        "The genetic test recommended for clopidogrel is CYP2C19 genotyping."
    ], 
    "exact_answer": [
        "CYP2C19 genotyping"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003955", 
        "http://www.biosemantics.org/jochem#4260620", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005820", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796"
    ], 
    "type": "factoid", 
    "id": "5156be04d24251bc05000085", 
    "snippets": [
        {
            "offsetInBeginSection": 607, 
            "offsetInEndSection": 677, 
            "text": "polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 212, 
            "text": "This study sought to evaluate the influence of single nucleotide polymorphisms (SNPs) on the pharmacodynamic effect of high- or standard-dose clopidogrel after percutaneous coronary intervention (PCI).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1621, 
            "offsetInEndSection": 2056, 
            "text": "CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynamic effects of clopidogrel, both early and late after PCI. In patients with high OTR identified by platelet function testing, the CYP2C19 genotype provides limited incremental information regarding the risk of persistently high reactivity with clopidogrel 150-mg maintenance dosing. (Genotype Information and Functional Testing Study [GIFT]; NCT00992420).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 324, 
            "text": "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088980", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 607, 
            "offsetInEndSection": 920, 
            "text": "polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics. These polymorphisms may be useful to identify clopidogrel nonresponders who may benefit from taking an alternative antiplatelet agent such as prasugrel and ticagrelor. Although both drugs have pharmacogenomic tests available for clinical use,", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 136, 
            "offsetInEndSection": 497, 
            "text": "The CYP2C19*2 allele is a common genetic variant associated with increased rates of major adverse events in individuals given clopidogrel after percutaneous coronary intervention (PCI). We used a novel point-of-care genetic test to identify carriers of the CYP2C19*2 allele and aimed to assess a pharmacogenetic approach to dual antiplatelet treatment after PCI", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22464343", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 401, 
            "text": "The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22154242", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 164, 
            "text": "The cytochrome P450 (CYP) 2C19*2 loss-of-function allele has been associated with impaired clopidogrel response and worse prognosis in clopidogrel-treated patients.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803320", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 357, 
            "offsetInEndSection": 637, 
            "text": "The present study was designed to evaluate the benefit of tailored therapy with a higher maintenance dose according to CYP2C19 genotypes in patients identified as nonresponders who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803320", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 893, 
            "offsetInEndSection": 977, 
            "text": "identify genes and mutations with known associations with disease and drug response.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1654, 
            "offsetInEndSection": 1753, 
            "text": "The patient had a heterozygous null mutation in CYP2C19 suggesting probable clopidogrel resistance,", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 344, 
            "text": "The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in clopidogrel metabolization. A recently explored CYP2C19*17 allelic variant has been linked to increased transcriptional activity, resulting in extensive metabolization of CYP2C19 substrates, which may lead to an enhanced platelet response to clopidogrel treatment.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20083681", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 333, 
            "offsetInEndSection": 395, 
            "text": "To identify gene variants that influence clopidogrel response.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706858", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 608, 
            "offsetInEndSection": 973, 
            "text": "A genome-wide association study was performed followed by genotyping the loss-of-function cytochrome P450 (CYP) 2C19*2 variant (rs4244285). Findings in the PAPI Study were extended by examining the relation of CYP2C19*2 genotype to platelet function and cardiovascular outcomes in an independent sample of 227 patients undergoing percutaneous coronary intervention.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706858", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 116, 
            "text": "Coexisting polymorphisms of the genes affecting clopiogrel resistance may influence platelet activation.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577829", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 439, 
            "offsetInEndSection": 754, 
            "text": "Genotyping revealed 7 carriers of both the C allele of P2Y12 and A allele of CYP2C19 (group 1), 14 carriers of the T allele of P2Y12 and A allele of CYP2C19 (group 2), 17 carriers of the C allele of P2Y12 and G allele of CYP2C19 (group 3) and 67 carriers of the T allele of P2Y12 and G allele of CYP2C19 (controls).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577829", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 37, 
            "offsetInEndSection": 285, 
            "text": "to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18004210", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 260, 
            "offsetInEndSection": 337, 
            "text": "to test the influence of the CYP 2C19*2 allele on clopidogrel responsiveness.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17681590", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 84, 
            "text": "Genetic polymorphisms significantly influence responses to warfarin and clopidogrel.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 286, 
            "text": "A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22974536", 
            "endSection": "sections.0"
        }
    ]
}